Buy Or Sell Opportunity • Mar 20
Now 20% undervalued Over the last 90 days, the stock has risen 17% to RON11.24. The fair value is estimated to be RON14.07, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 19% over the last 3 years. Earnings per share has declined by 33%. For the next 3 years, revenue is forecast to grow by 9.5% per annum. Earnings are also forecast to grow by 62% per annum over the same time period. New Risk • Mar 04
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 29% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.8x net interest cover). Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.4% net profit margin). Reported Earnings • Mar 04
Full year 2025 earnings: EPS exceeds analyst expectations Full year 2025 results: EPS: RON0.022 (down from RON0.047 in FY 2024). Revenue: RON3.19b (up 17% from FY 2024). Net income: RON11.6m (down 54% from FY 2024). Profit margin: 0.4% (down from 0.9% in FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 88%. Revenue is forecast to grow 9.2% p.a. on average during the next 2 years, compared to a 5.1% growth forecast for the Healthcare industry in Europe. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has increased by 38% per year, which means it is well ahead of earnings. Buy Or Sell Opportunity • Feb 09
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 63% to RON14.12. The fair value is estimated to be RON11.66, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 20% over the last 3 years. Earnings per share has declined by 36%. Revenue is forecast to grow by 23% in 2 years. Earnings are forecast to grow by 4,936% in the next 2 years. Price Target Changed • Feb 06
Price target increased by 7.7% to RON8.21 Up from RON7.62, the current price target is an average from 4 analysts. New target price is 41% below last closing price of RON13.94. Stock is up 144% over the past year. The company is forecast to post earnings per share of RON0.055 for next year compared to RON0.047 last year. Announcement • Jan 28
Med Life S.A., Annual General Meeting, Apr 30, 2026 Med Life S.A., Annual General Meeting, Apr 30, 2026. Buy Or Sell Opportunity • Jan 23
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 44% to RON11.82. The fair value is estimated to be RON9.84, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 20% over the last 3 years. Earnings per share has declined by 36%. Revenue is forecast to grow by 23% in 2 years. Earnings are forecast to grow by 4,904% in the next 2 years. Major Estimate Revision • Dec 04
Consensus EPS estimates fall by 77% The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate fell from RON0.13 to RON0.03 per share. Revenue forecast steady at RON3.21b. Net income forecast to grow 1,721% next year vs 29% growth forecast for Healthcare industry in Romania. Consensus price target broadly unchanged at RON7.60. Share price rose 9.5% to RON9.30 over the past week. Reported Earnings • Nov 17
Third quarter 2025 earnings released Third quarter 2025 results: Revenue: RON796.4m (up 19% from 3Q 2024). Net income: RON7.24m (up 53% from 3Q 2024). Profit margin: 0.9% (up from 0.7% in 3Q 2024). Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 5.2% growth forecast for the Healthcare industry in Europe. Reported Earnings • Aug 31
Second quarter 2025 earnings released Second quarter 2025 results: Revenue: RON801.4m (up 20% from 2Q 2024). Net loss: RON15.9m (down 368% from profit in 2Q 2024). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 5.2% growth forecast for the Healthcare industry in Europe. Price Target Changed • Jul 22
Price target increased by 7.6% to RON7.20 Up from RON6.69, the current price target is an average from 6 analysts. New target price is approximately in line with last closing price of RON7.08. Stock is up 21% over the past year. The company is forecast to post earnings per share of RON0.12 for next year compared to RON0.047 last year. Major Estimate Revision • Jun 05
Consensus EPS estimates fall by 35% The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate fell from RON0.17 to RON0.11 per share. Revenue forecast steady at RON3.13b. Net income forecast to grow 204% next year vs 25% growth forecast for Healthcare industry in Romania. Consensus price target up from RON6.69 to RON6.84. Share price rose 6.3% to RON6.94 over the past week. Price Target Changed • Jun 04
Price target increased by 7.7% to RON6.84 Up from RON6.35, the current price target is an average from 5 analysts. New target price is approximately in line with last closing price of RON6.63. Stock is up 28% over the past year. The company is forecast to post earnings per share of RON0.11 for next year compared to RON0.047 last year. Reported Earnings • May 05
Full year 2024 earnings: EPS and revenues exceed analyst expectations Full year 2024 results: EPS: RON0.047 (up from RON0.007 in FY 2023). Revenue: RON2.72b (up 23% from FY 2023). Net income: RON25.0m (up RON21.4m from FY 2023). Profit margin: 0.9% (up from 0.2% in FY 2023). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 3.2%. Earnings per share (EPS) also surpassed analyst estimates by 25%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 4.8% growth forecast for the Healthcare industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 92 percentage points per year, which is a significant difference in performance. Announcement • Mar 21
Med Life S.A. (BVB:M) acquired an unknown majority stake in All Clinic. Med Life S.A. (BVB:M) acquired an unknown majority stake in All Clinic on March 20, 2025. For the period ending December 31, 2024, All Clinic reported total revenue of €0.8 million.
Med Life S.A. (BVB:M) completed the acquisition of an unknown majority stake in All Clinic on March 20, 2025. Price Target Changed • Mar 04
Price target increased by 8.1% to RON6.68 Up from RON6.18, the current price target is an average from 5 analysts. New target price is 15% above last closing price of RON5.80. Stock is up 50% over the past year. The company is forecast to post earnings per share of RON0.17 for next year compared to RON0.048 last year. Reported Earnings • Mar 03
Full year 2024 earnings released: EPS: RON0.048 (vs RON0.007 in FY 2023) Full year 2024 results: EPS: RON0.048 (up from RON0.007 in FY 2023). Revenue: RON2.72b (up 23% from FY 2023). Net income: RON25.5m (up RON21.9m from FY 2023). Profit margin: 0.9% (up from 0.2% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 5.3% growth forecast for the Healthcare industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 93 percentage points per year, which is a significant difference in performance. Announcement • Jan 24
Med Life S.A., Annual General Meeting, Apr 29, 2025 Med Life S.A., Annual General Meeting, Apr 29, 2025. Price Target Changed • Jan 14
Price target increased by 8.2% to RON6.18 Up from RON5.71, the current price target is an average from 5 analysts. New target price is 7.1% above last closing price of RON5.77. Stock is up 44% over the past year. The company is forecast to post earnings per share of RON0.04 for next year compared to RON0.0069 last year. Major Estimate Revision • Nov 28
Consensus EPS estimates fall by 20% The consensus outlook for fiscal year 2024 has been updated. 2024 EPS estimate fell from RON0.05 to RON0.04 per share. Revenue forecast steady at RON2.63b. Net income forecast to grow 233% next year vs 25% growth forecast for Healthcare industry in Romania. Consensus price target broadly unchanged at RON5.76. Share price was steady at RON6.18 over the past week. Reported Earnings • Nov 17
Third quarter 2024 earnings released Third quarter 2024 results: Revenue: RON670.4m (up 19% from 3Q 2023). Net income: RON4.74m (up 339% from 3Q 2023). Profit margin: 0.7% (up from 0.2% in 3Q 2023). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 5.1% growth forecast for the Healthcare industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 86 percentage points per year, which is a significant difference in performance. Announcement • Oct 29
Med Life S.A. (BVB:M) acquired 60% stake in Routine Med S.r.l. Med Life S.A. (BVB:M) acquired 60% stake in Routine Med S.r.l. on October 28, 2024.
For the period ending December 31, 2023, Routine Med S.r.l. reported total revenue of RON 15 million.
Med Life S.A. (BVB:M) completed the acquisition of 60% stake in Routine Med S.r.l. on October 28, 2024. Announcement • Sep 17
Med Life S.A. (BVB:M) acquired 80% stake in Euromedica Hospital Sa. Med Life S.A. (BVB:M) acquired 80% stake in Euromedica Hospital Sa on September 17, 2024.
For the period ending December 31, 2023, Euromedica Hospital Sa reported total revenue of RON 15 million.
Med Life S.A. (BVB:M) completed the acquisition of 80% stake in Euromedica Hospital Sa on September 17, 2024. Major Estimate Revision • Sep 11
Consensus EPS estimates increase by 25% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from RON2.49b to RON2.56b. EPS estimate increased from RON0.04 to RON0.05 per share. Net income forecast to grow 189% next year vs 22% growth forecast for Healthcare industry in Romania. Consensus price target up from RON5.15 to RON5.71. Share price was steady at RON5.75 over the past week. Price Target Changed • Sep 10
Price target increased by 11% to RON5.71 Up from RON5.16, the current price target is an average from 4 analysts. New target price is approximately in line with last closing price of RON5.68. Stock is up 26% over the past year. The company is forecast to post earnings per share of RON0.05 for next year compared to RON0.0069 last year. Reported Earnings • Sep 03
Second quarter 2024 earnings released Second quarter 2024 results: EPS: RON0.006. Revenue: RON665.7m (up 23% from 2Q 2023). Net income: RON2.98m (up RON4.23m from 2Q 2023). Profit margin: 0.4% (up from net loss in 2Q 2023). The move to profitability was driven by higher revenue. Revenue is forecast to grow 8.6% p.a. on average during the next 2 years, compared to a 5.3% growth forecast for the Healthcare industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 80 percentage points per year, which is a significant difference in performance. Buy Or Sell Opportunity • Jul 01
Now 28% undervalued Over the last 90 days, the stock has risen 50% to RON5.88. The fair value is estimated to be RON8.20, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Earnings per share has declined by 56%. Revenue is forecast to grow by 9.6% in a year. Earnings are forecast to grow by 125% in the next year. Buy Or Sell Opportunity • Jun 25
Now 22% undervalued Over the last 90 days, the stock has risen 58% to RON6.10. The fair value is estimated to be RON7.80, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Earnings per share has declined by 56%. Revenue is forecast to grow by 9.6% in a year. Earnings are forecast to grow by 125% in the next year. Reported Earnings • May 05
Full year 2023 earnings released: EPS: RON0.007 (vs RON0.061 in FY 2022) Full year 2023 results: EPS: RON0.007 (down from RON0.061 in FY 2022). Revenue: RON2.22b (up 23% from FY 2022). Net income: RON3.68m (down 89% from FY 2022). Profit margin: 0.2% (down from 1.8% in FY 2022). Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 5.6% growth forecast for the Healthcare industry in Europe. Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings. Reported Earnings • Apr 04
Full year 2023 earnings released: EPS: RON0.007 (vs RON0.061 in FY 2022) Full year 2023 results: EPS: RON0.007 (down from RON0.061 in FY 2022). Revenue: RON2.22b (up 23% from FY 2022). Net income: RON3.68m (down 89% from FY 2022). Profit margin: 0.2% (down from 1.8% in FY 2022). Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 5.7% growth forecast for the Healthcare industry in Europe. Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has increased by 17% per year, which means it is well ahead of earnings. Reported Earnings • Mar 03
Full year 2023 earnings released Full year 2023 results: Revenue: RON2.23b (up 23% from FY 2022). Net income: RON2.77m (down 91% from FY 2022). Profit margin: 0.1% (down from 1.8% in FY 2022). Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 2.7% growth forecast for the Healthcare industry in Europe. Reported Earnings • Nov 14
Third quarter 2023 earnings released Third quarter 2023 results: Revenue: RON565.3m (up 21% from 3Q 2022). Net loss: RON2.24m (down 126% from profit in 3Q 2022). Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 2.6% growth forecast for the Healthcare industry in Europe. Reported Earnings • Aug 28
Second quarter 2023 earnings released Second quarter 2023 results: Revenue: RON542.2m (up 22% from 2Q 2022). Net loss: RON2.29m (down 116% from profit in 2Q 2022). Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 4.9% growth forecast for the Healthcare industry in Europe. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 45% per year, which means it is tracking significantly ahead of earnings growth. Price Target Changed • Aug 04
Price target decreased by 7.3% to RON20.21 Down from RON21.80, the current price target is an average from 4 analysts. New target price is 5.2% above last closing price of RON19.20. Stock is down 1.8% over the past year. The company posted earnings per share of RON0.24 last year. Reported Earnings • May 14
First quarter 2023 earnings released First quarter 2023 results: Revenue: RON532.8m (up 27% from 1Q 2022). Net income: RON7.29m (down 73% from 1Q 2022). Profit margin: 1.4% (down from 6.5% in 1Q 2022). Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 5.3% growth forecast for the Healthcare industry in Europe. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has increased by 47% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Mar 01
Full year 2022 earnings released: EPS: RON0.30 (vs RON0.77 in FY 2021) Full year 2022 results: EPS: RON0.30 (down from RON0.77 in FY 2021). Revenue: RON1.82b (up 27% from FY 2021). Net income: RON39.4m (down 62% from FY 2021). Profit margin: 2.2% (down from 7.1% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 16% p.a. on average during the next 2 years, compared to a 5.6% growth forecast for the Healthcare industry in Europe. Over the last 3 years on average, earnings per share has increased by 41% per year whereas the company’s share price has increased by 44% per year. Price Target Changed • Feb 01
Price target increased by 31% to RON20.45 Up from RON15.65, the current price target is an average from 2 analysts. New target price is 6.6% above last closing price of RON19.18. Stock is down 18% over the past year. The company posted earnings per share of RON0.77 last year. Announcement • Jan 12
Med Life S.A. (BVB:M) acquired 99.76% stake in Muntenia Medical Competences SA. Med Life S.A. (BVB:M) acquired 99.76% stake in Muntenia Medical Competences SA on January 10, 2023.The completion of transaction took place after the approval of the Competition Council.
Med Life S.A. (BVB:M) completed the acquisition of 99.76% stake in Muntenia Medical Competences SA on January 10, 2023. Reported Earnings • Nov 16
Third quarter 2022 earnings released Third quarter 2022 results: Revenue: RON469.2m (up 28% from 3Q 2021). Net income: RON8.63m (down 65% from 3Q 2021). Profit margin: 1.8% (down from 6.7% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.5% p.a. on average during the next 2 years, compared to a 5.3% growth forecast for the Healthcare industry in Europe. Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 3 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Ana Mihaiescu was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Nov 13
Third quarter 2022 earnings released Third quarter 2022 results: Revenue: RON469.2m (up 28% from 3Q 2021). Net income: RON8.63m (down 65% from 3Q 2021). Profit margin: 1.8% (down from 6.7% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.5% p.a. on average during the next 2 years, compared to a 5.4% growth forecast for the Healthcare industry in Europe. Announcement • Oct 25
Med Life S.A. (BVB:M) completed the acquisition of 80% stake in Medici's Group. Med Life S.A. (BVB:M) entered into an agreement to acquire 80% stake in Medici's Group on June 21, 2022. The transaction is subject to pending approval from the Competition Council.
Med Life S.A. (BVB:M) completed the acquisition of 80% stake in Medici's Group on October 24, 2022. The transaction was approved by the Competition Council. Price Target Changed • Sep 15
Price target decreased to RON19.50 Down from RON22.63, the current price target is an average from 2 analysts. New target price is approximately in line with last closing price of RON19.98. Stock is up 17% over the past year. The company posted earnings per share of RON0.77 last year. Announcement • Sep 14
Med Life S.A. (BVB:M) acquired majority stake in SanoPass SRL. Med Life S.A. (BVB:M) acquired majority stake in SanoPass SRL on September 12, 2022.
Med Life S.A. (BVB:M) completed the acquisition of majority stake in SanoPass SRL on September 12, 2022. Reported Earnings • Aug 29
Second quarter 2022 earnings released Second quarter 2022 results: Revenue: RON443.7m (up 30% from 2Q 2021). Net income: RON14.3m (down 56% from 2Q 2021). Profit margin: 3.2% (down from 9.5% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is expected to shrink by 4.8% compared to a 5.8% growth forecast for the Healthcare industry in Romania. Announcement • Aug 06
Med Life S.A. (BVB:M) acquired 60% stake in Opticristal - ophthalmological clinic. Med Life S.A. (BVB:M) acquired 60% stake in Opticristal - ophthalmological clinic on August 4, 2022. The Opticristal clinic recorded a turnover of €1 million in 2021.
Med Life S.A. (BVB:M) completed the acquisition of 60% stake in Opticristal - ophthalmological clinic on August 4, 2022. Announcement • Jul 05
Med Life S.A. (BVB:M) agreed to acquire SWEAT CONCEPT ONE. Med Life S.A. (BVB:M) agreed to acquire SWEAT CONCEPT ONE on July 4, 2022. Following the completion of this transaction, the current management team will fully retain its responsibilities, being responsible for the strategy of development and expansion of Sweat Concept network. Announcement • Jun 25
Med Life S.A. (BVB : M) acquired Medicris Oradea Group. Med Life S.A. (BVB : M) acquired Medicris Oradea Group on June 24, 2022.Med Life S.A. (BVB : M) completed the acquisition of Medicris Oradea Group on June 24, 2022. Announcement • Jun 23
Med Life S.A. (BVB:M) entered into an agreement to acquire 80% stake in Medici's Group. Med Life S.A. (BVB:M) entered into an agreement to acquire 80% stake in Medici's Group on June 21, 2022. The transaction is subject to pending approval from the Competition Council. Price Target Changed • Jun 09
Price target increased to RON26.13 Up from RON22.13, the current price target is an average from 2 analysts. New target price is 30% above last closing price of RON20.15. Stock is up 30% over the past year. The company posted earnings per share of RON0.77 last year. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 3 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Ana Mihaescu was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Announcement • Apr 07
Med Life S.A. (BVB:M) acquired 60% interest in Pro Life Clinics. Med Life S.A. (BVB:M) acquired 60% interest in Pro Life Clinics on April 6, 2022. Pro Life Clinics recorded a turnover of RON 7.3 million in 2021.
Med Life S.A. (BVB:M) completed the acquisition of 60% interest in Pro Life Clinics on April 6, 2022. Valuation Update With 7 Day Price Move • Mar 04
Investor sentiment deteriorated over the past week After last week's 18% share price decline to RON17.55, the stock trades at a trailing P/E ratio of 19.6x. Average forward P/E is 16x in the Healthcare industry in Europe. Total returns to shareholders of 289% over the past three years. Announcement • Feb 24
Med Life S.A. (BVB:M) completed the acquisition of 50% stake in Neolife Medical Center Romania. Med Life S.A. (BVB:M) agreed to acquire 50% stake in Neolife Medical Center Romania on October 27, 2021. The Neolife Medical Center Romania, with a total of 250 employees and partners, closed 2020 with a turnover of RON 92 million, an increase of over 30% as compared to 2019. The transaction is subject to approval by the Competition Council.
Med Life S.A. (BVB:M) completed the acquisition of 50% stake in Neolife Medical Center Romania on February 23, 2022. The Competition Council has approved the transaction. Reported Earnings • Nov 17
Third quarter 2021 earnings released The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: RON366.5m (up 21% from 3Q 2020). Net income: RON24.5m (down 18% from 3Q 2020). Profit margin: 6.7% (down from 9.8% in 3Q 2020). The decrease in margin was driven by higher expenses. Price Target Changed • Nov 13
Price target increased to RON17.40 Up from RON13.73, the current price target is an average from 3 analysts. New target price is 24% below last closing price of RON22.90. Stock is up 248% over the past year. The company posted earnings per share of RON0.42 last year. Price Target Changed • Sep 10
Price target increased to RON14.65 Up from RON13.08, the current price target is an average from 4 analysts. New target price is 13% below last closing price of RON16.90. Stock is up 173% over the past year. Announcement • Jun 09
Med Life S.A. (BVB:M) acquired remaining 10% stakes in Clinica Medicala Panduri. Med Life S.A. (BVB:M) acquired remaining 10% stakes in Clinica Medicala Panduri on June 7, 2021.
Med Life S.A. (BVB:M) completed the acquisition of remaining 10% stakes in Clinica Medicala Panduri on June 7, 2021. Announcement • Jun 08
Med Life S.A. (BVB:M) acquired the remaining 10% stake in Centrul Medical Panduri S.A. Med Life S.A. (BVB:M) acquired the remaining 10% stake in Centrul Medical Panduri S.A. on June 7, 2021. Post transction Med Life will own 100% stake of Centrul Medical.
Med Life S.A. (BVB:M) completed the acquisition of the remaining 10% stake in Centrul Medical Panduri S.A. on June 7, 2021.